Computer system and payment calculation method

Abstract

To provide a computer system that calculates a cost and time required to store a cell used in cell therapy, and maximizes profit for a pharmaceutical company.SOLUTION: A computer system uses treatment outcome data managed by a medical facility to calculate implementation probability of cell therapy, generates a second model by incorporating an evaluation model, which evaluates cell deterioration over time in the stored cell, into a first model which calculates probability of success of the cell therapy, generated using characteristics of a cell collected from a patient who underwent the cell therapy and treatment outcome data of the patient, uses the implementation probability of the cell therapy and the second model to change the storage period of the cell and the amount of payment paid by a business operator for the storage facility, performs a simulation that estimates profit of the business operator from success of the cell therapy, and calculates, on the basis of a result of the simulation, the storage period and the amount of payment that maximize the profit of the business operator.SELECTED DRAWING: Figure 5

Description

[Technical field]

[0001] The present invention relates to a technique for determining the cost and duration of storage of cells for therapeutic use. [Background technology]

[0002] In the medical fee billing and payment system, some medical institutions are faced with financial difficulties due to delays in payment from the payment fund after billing for medical fees. In addition, medical administration is inefficient, and there are problems with data storage, security, etc. To address this issue, the technologies described in Patent Documents 1 and 2 are known.

[0003] Patent document 1 states that "For medical institutions and medical payment funds, businesses act as intermediaries to enter into financial contracts with financial institutions regarding medical fee receivables, and to ensure the smooth operation of the contract, businesses provide various services, such as a network distribution service for application software for medical fee statements."

[0004] Patent Document 2 describes a system for optimizing medical expenses, including a stage for outputting a standard medical fee and a patient's out-of-pocket expenses related to the selected optimal treatment method, a stage for outputting a standard upper limit of the drug cost portion related to the medical fee, and a stage for outputting drugs that can be prescribed within the range not exceeding the standard upper limit of the drug cost portion, in particular generic drugs, and the patient's out-of-pocket expenses related to the drugs. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2002-230298 A [Patent Document 2] JP 2002-251458 A Summary of the Invention [Problem to be solved by the invention]

[0006] In cell therapies using autologous cells, such as CAR-T therapy, cells are collected from the patient at a medical institution, transported to a cell processing center in an ultra-low temperature container, processed at the cell processing center, and then the processed cells are returned to the medical institution and transfused back to the patient.

[0007] At this time, it takes one to three months for the cells to be transported, processed, and transfused, and there are cases where the patient's condition deteriorates and they die during this waiting time. In addition, it is common to administer strong anti-cancer drug treatment before cell therapy, and there are cases where cell processing fails or the therapeutic effect is insufficient due to cell deterioration caused by the anti-cancer drug treatment. In cases where cell processing and treatment fail, pharmaceutical companies incur losses as they are unable to receive reimbursement for the treatment.

[0008] Therefore, by collecting cells before the patient begins to undergo powerful anti-cancer drug treatment and storing them frozen, it is believed that the success rate of cell processing and the effectiveness of treatment can be improved, losses to the contracting company can be reduced, and the survival rate of the patient can be improved. However, there is an issue that the cost of storing cells is not always reimbursed through medical fees, and patients and pharmaceutical companies must bear the storage costs. [Means for solving the problem]

[0009] A representative example of the invention disclosed in the present application is as follows: That is, a computer system includes a computer having a processor, a storage device connected to the processor, and a network interface connected to the processor, and is accessible to a storage facility for storing cells collected from a patient, a processing facility for processing the stored cells, and a medical facility for performing cell therapy using the processed cells, in which a storage fee paid to the storage facility according to a storage period is borne by both the patient and a business operating the processing facility, the business receives a success fee for the cell therapy from the patient, the processor calculates a probability of performing the cell therapy using treatment outcome data managed by the medical facility and stores the calculated probability in the storage device, and the processor accesses a storage facility for storing cells collected from the patient after the cell therapy is performed, and the processing facility is accessible to a storage facility for storing the cells collected from the patient after the cell therapy is performed, and a storage fee paid to the storage facility according to a storage period is borne by both the patient and a business operating the processing facility, the business receives a success fee for the cell therapy from the patient, the processor calculates a probability of performing the cell therapy using treatment outcome data managed by the medical facility, and stores the calculated probability in the storage device, a second model is generated by incorporating an evaluation model for evaluating deterioration of the stored cells over time into a first model for calculating the probability of success of the cell therapy, the second model being generated using the characteristics of the stored cells and the treatment outcome data of the patient, and the second model is stored in the storage device; the processor uses the probability of performing the cell therapy and the second model to vary the storage period of the cells at the storage facility and the amount of payment made by the business operator to the storage facility, and performs a simulation to estimate the business operator's profit from the success of the cell therapy; the results of the simulation are stored in the storage device; and the processor calculates an optimal storage period and an optimal payment amount that maximize the business operator's profit based on the results of the simulation. Effect of the Invention

[0010] According to the present invention, collected cells can be stored based on a payment amount that is reasonable from the viewpoint of the profits of pharmaceutical companies. Problems, configurations, and effects other than those described above will become apparent from the following description of the embodiments. [Brief description of the drawings]

[0011] [Figure 1] FIG. 2 is a conceptual diagram of the service of the present invention. [Diagram 2]FIG. 1 is a diagram showing an example of the configuration of a system for implementing the present invention. [Diagram 3] FIG. 2 is a diagram showing an example of a state transition model of a patient who uses the medical institution of the first embodiment. [Figure 4] 11 is a flowchart illustrating an example of a discrimination model generation process executed by the cell storage management system of the first embodiment. [Diagram 5] 11 is a flowchart illustrating an example of a cost calculation process executed by the cell storage management system of the first embodiment. [Figure 6] FIG. 2 is a diagram showing an example of a charge acceptance curve stored in the cell storage management system of Example 1. [Figure 7] FIG. 2 is a diagram showing an example of a history distribution calculated by the cell storage and management system of the first embodiment. [Figure 8] FIG. 1 is a diagram showing the breakdown of storage fees paid to the cold storage facility of Example 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] Hereinafter, an embodiment of the present invention will be described with reference to the drawings. However, the present invention is not to be interpreted as being limited to the description of the embodiment shown below. It will be easily understood by those skilled in the art that the specific configuration can be changed without departing from the concept or purpose of the present invention.

[0013] In the configurations of the invention described below, the same or similar configurations or functions are given the same reference numerals, and duplicated explanations are omitted.

[0014] In this specification, the terms "first," "second," "third," and the like are used to identify components and do not necessarily limit the number or order.

[0015] In order to facilitate understanding of the invention, the position, size, shape, range, etc. of each component shown in the drawings, etc. may not represent the actual position, size, shape, range, etc. Therefore, the present invention is not limited to the position, size, shape, range, etc. disclosed in the drawings, etc. EXAMPLES

[0016] Fig. 1 is a conceptual diagram of a service according to the present invention, and Fig. 2 is a diagram showing an example of the configuration of a system for realizing the present invention.

[0017] The stakeholders of the service include a medical institution 10, a testing company 20, a cold storage facility 30, and a cell processing center 40.

[0018] The medical institution 10 is a facility that treats patients, such as a hospital, etc. The medical institution 10 operates a patient management system 200 and a treatment outcome management system 201, as shown in FIG.

[0019] The patient management system 200 is a system for managing patients who use the medical institution 10, and holds a patient management DB 210. The patient management DB 210 stores patient data for managing patients. The patient data includes the patient's personal information (name, age, sex, etc.), the patient's ID, medical condition, treatment performed, treatment results, vital signs, etc. The treatment outcome management system 201 is a system for managing the results of treatment performed on patients, and holds a treatment outcome management DB 211. The treatment outcome management DB 211 stores treatment outcome data for managing the results of treatment performed on patients. The treatment outcome data includes the patient's ID, the contents of the treatment, and the results of the treatment, etc. In this embodiment, treatment outcome data related to cell therapy is accumulated in the treatment outcome management DB 211.

[0020] Testing company 20 is a company that tests cells collected from patients.

[0021] The cold storage facility 30 is a facility for cryopreserving cells. The cold storage facility 30 operates a cell storage management system 202.

[0022] The cell storage management system 202 is a system for managing cryopreserved cells, and holds a cell management DB 212. The cell management DB 212 stores cell data for managing cryopreserved cells. The cell data includes the patient ID, the date and time when cryopreservation started, the test results of the cells, etc.

[0023] The cell processing center 40 is a facility that processes cells collected from patients. In this specification, the cell processing center 40 is assumed to be operated by a pharmaceutical company. However, it may also be a company such as a CDMO (Contract Development and Manufacturing Organization). The cell processing center 40 manages a cell processing management system 203. The cell processing management system 203 is a system that manages processed cells, and holds a processing management DB 213. The processing management DB 213 stores processing data for managing processed cells. The processing data includes the patient ID, processing date, processing content, etc.

[0024] The patient management system 200, the treatment outcome management system 201, the cell storage management system 202, and the cell processing management system 203 are each composed of at least one computer. The computer has a processor, a main memory device, a sub-memory device, and a network interface. Each system may also include a storage device and a network switch.

[0025] Here, the service flow will be described.

[0026] The medical institution 10 acquires cells from a patient (step S101), and performs a freezing process on the cells to about -80 degrees (step S102). A record of the cell collection is registered in the patient management DB 210. The cells are managed in association with a patient ID. The cell collection method is, for example, collection of white blood cells by apheresis. However, the present invention is not limited to the cell collection method.

[0027] The frozen cells are stored in a container such as a dry shipper and transported. Specifically, the medical institution 10 sends a portion of the frozen cells to a testing company 20 and sends the remaining cells to a frozen storage facility 30.

[0028] The testing company 20 thaws some of the cells taken out of the container (step S103) and performs cell measurement (step S104). In the cell measurement, measurements related to the characteristics of the cells are performed. For example, cell surface proteins are measured by flow cytometry, or gene mutations and gene expressions are measured by NGS (Next Generation Sequencer). Note that the present invention is not limited to the measurement method and items to be measured.

[0029] The testing company 20 transmits the test results, including the patient ID and the measurement data, to the cold storage facility 30, thereby registering the test results in the cell management DB 212 (step S105).

[0030] The cold storage facility 30 stores the cells sent from the medical institution 10 (step S106). The cold storage facility 30 registers data on the stored cells in the cell management DB 212 (step S107). The pharmaceutical company pays a portion of the cold storage fee (storage fee), and the patient also pays a portion of the storage fee. The amount paid by the pharmaceutical company is recorded as the payment amount, and the amount paid by the patient is recorded as the burden amount.

[0031] When the cold storage facility 30 receives a request for cell processing from the medical institution 10, it stores the cells in a container such as a dry shipper and sends them to the cell processing center 40.

[0032] The cell processing center 40 thaws the cells (step S108) and performs cell processing (step S109). Furthermore, the cell processing center 40 performs freezing processing on the processed cells (step S110) and registers data on the processed cells in the processing management DB 213 (step S111). The cell processing center 40 stores the processed cells in a container such as a dry shipper and sends them to the medical institution 10.

[0033] The medical institution 10 thaws the processed cells (step S112) and injects the processed cells into a patient corresponding to the patient ID associated with the cells (step S113). The medical institution 10 registers data on the success / failure of the treatment using the processed cells in the patient management DB 210 (step S114). The patient management system 200 of the medical institution 10 collects treatment outcome data related to the cell therapy together with the patient ID and transmits it to the treatment outcome management system 201. The treatment outcome management system 201 registers the received treatment outcome data together with the patient ID in the treatment outcome management DB 211 (step S115).

[0034] FIG. 3 is a diagram showing an example of a state transition model of a patient who uses the medical institution 10 according to the first embodiment.

[0035] In this embodiment, the status includes primary treatment, secondary treatment, cell therapy, follow-up, and death. Primary treatment and secondary treatment refer to treatments other than cell therapy using processed cells, such as anticancer drug treatment. Follow-up refers to follow-up after treatment.

[0036] As shown in Fig. 3, the state transition model of a patient is represented as a graph with nodes of primary treatment 301, follow-up 302, secondary treatment 303, follow-up 304, cell therapy 305, follow-up 306, and death 307. Follow-up 302 represents a follow-up when primary treatment is performed, follow-up 304 represents a follow-up when secondary treatment is performed, and follow-up 306 represents a follow-up when cell therapy is performed. Directed edges connecting between states (nodes) represent state transitions, and state transition probability pi is set. i is a natural number from 1 to 10.

[0037] The cell storage and management system 202 of the first embodiment acquires treatment outcome data from the treatment outcome management system 201. It acquires cell data from the cell management DB 212. Furthermore, the cell storage and management system 202 calculates a payment amount that maximizes profits based on the acquired treatment outcome data and cell data.

[0038] Specifically, the cell storage management system 202 uses the treatment outcome data and cell data of the cell therapy to generate a discrimination model that discriminates between success and failure of the cell therapy. The cell storage management system 202 calculates each state transition probability of the state transition model shown in Fig. 3 using the patient data and the discrimination model. The cell storage management system 202 calculates the benefit distribution by performing a simulation using the state transition probabilities, and calculates the expected distribution of the patient's share of the costs. The cell storage management system 202 calculates the payment amount based on the benefit distribution and the expected distribution of the costs.

[0039] Next, the method of calculating the payment amount will be described in detail.

[0040] FIG. 4 is a flowchart illustrating an example of a discrimination model generation process executed by the cell storage management system 202 according to the first embodiment.

[0041] In the first embodiment, a discrimination model is generated for each medical institution 10. However, a discrimination model common to all medical institutions 10 may be generated, or a discrimination model may be generated for each region. In this case, the range of data to be acquired may be changed.

[0042] The cell storage management system 202 acquires cell data from the cell management DB 212 (step S401).

[0043] Next, the cell storage management system 202 acquires treatment outcome data corresponding to the patient ID included in the cell data from the treatment outcome management system 201 (step S402).

[0044] Next, the cell storage management system 202 generates a discrimination model for discriminating the success / non-success of the cell therapy based on the cell data and the treatment outcome data and on the characteristics of the cells (step S403).

[0045] For example, the cell storage and management system 202 refers to the treatment outcome data and assigns a label of either success or failure to the cell data. The cell storage and management system 202 generates a discrimination model by logistic regression analysis in which the label is the objective variable Y(i) and the characteristics of the cells included in the cell data are the explanatory variables X(j).

[0046] Here, variable i is an integer from 1 to n, and variable j is an integer from 1 to m. n represents the number of patients, and m represents the number of attributes included in the cell characteristics. When the cell data includes gene expression, the number of attributes corresponds to the number of genes. In addition, by including gene sets related to cell growth and cell death in the explanatory variable X(j), it becomes possible to better capture the cell characteristics.

[0047] For example, in the logistic regression analysis, the coefficient b(j) and the constant b(0) in equation (1) are calculated.

[0048]

number

[0049] The discriminant model is given by equation (2), where Z is the expected probability of a treatment effect (probability of response).

[0050]

number

[0051] The discrimination model may be generated using a method other than the logistic regression analysis, such as a support vector machine, a random forest, or deep learning.

[0052] Next, the cell storage management system 202 generates a discrimination model for discriminating the success / failure of the cell therapy based on the cell characteristics, the freezing temperature, and the storage period by incorporating a model for evaluating the deterioration of frozen cells over time into the discrimination model generated in step S403 (step S404). Thereafter, the cell storage management system 202 saves the generated discrimination model and ends the discrimination model generation process.

[0053] Specifically, the cell storage management system 202 generates a new discrimination model by multiplying the discrimination model generated in step S403 by the cell deterioration curve. The cell deterioration curve is a curve that represents the relationship between the freezing temperature and storage period of the cells and the deterioration of the cells, and is given by, for example, formula (3). Here, coefficients A and B are deterioration coefficients determined from the freezing temperature, and t is a variable that represents the storage period.

[0054]

number

[0055] Therefore, the discriminant model is given by equation (4): W is the response probability.

[0056]

number

[0057] Fig. 5 is a flowchart for explaining an example of a cost calculation process executed by the cell storage management system 202 of Example 1. Fig. 6 is a diagram showing an example of a burden acceptance curve held by the cell storage management system 202 of Example 1. Fig. 7 is a diagram showing an example of a history distribution calculated by the cell storage management system 202 of Example 1. Fig. 8 is a diagram showing a breakdown of the storage fee paid to the cold storage facility 30 of Example 1.

[0058] In the first embodiment, the cost calculation process is executed for each medical institution 10. However, the cost calculation process may be executed for all medical institutions 10, or may be executed for each region. In this case, the range of data to be acquired may be changed.

[0059] The cell storage management system 202 acquires the burden acceptance curve and the discriminant model generated in the discriminant model generation process (step S501).

[0060] The cost-of-care acceptance curve is a curve for calculating the probability that a patient will accept a cost-of-care payment, and is given, for example, as a curve as shown in Figure 6. The horizontal axis represents the cost-of-care payment, and the vertical axis represents the acceptance probability. The cost-of-care acceptance curve is assumed to be preset.

[0061] Next, the cell storage management system 202 acquires patient data from the patient management system 200, and calculates transition probabilities p1, p2, p3, p4, p6, p7, p8, p9, and p11 using the patient data (step S502). That is, the probability that cell therapy will be performed is calculated. The transition probabilities may be calculated by the patient management system 200.

[0062] Next, the cell storage management system 202 starts a loop process of patients (step S503). The cell storage management system 202 selects a target patient from the patient group managed in the cell management DB 212, and acquires the cell data of the patient.

[0063] Next, the cell storage management system 202 starts loop processing of the storage period (step S504). The cell storage management system 202 randomly selects a storage period. In this embodiment, the storage period is selected in the range of one year to five years. The change range is, for example, one month. In data processing, the storage period is treated as a numerical value.

[0064] Next, the cell storage management system 202 calculates the success probability (step S505).

[0065] Specifically, the cell storage management system 202 sets the storage period selected in step S504 to the variable t of the discrimination model shown in formula (4), and also inputs the cell data to calculate the success probability. The success probability corresponds to the transition probability p5. Furthermore, the cell storage management system 202 calculates the transition probability p10 using formula (5).

[0066]

number

[0067] The above process determines the state transition model for the patient. In this embodiment, a Monte Carlo simulation using the state transition model is performed to estimate the payment amount and storage period that maximize the profits of the pharmaceutical company.

[0068] Next, the cell storage management system 202 starts a loop process of the payment amount (step S506). The cell storage management system 202 randomly selects a payment amount within the range of 0 yen to the full amount of storage costs. The change amount is, for example, 100,000 yen.

[0069] Next, the cell storage management system 202 calculates a profit distribution by performing a simulation based on the storage period, the transition probability, and the payment amount (step S507). The profit distribution is stored in association with the storage period and the payment amount.

[0070] In this embodiment, the profit distribution is calculated using a Monte Carlo simulation. For example, the cell storage management system 202 calculates profits by integrating costs and sales when 10,000 hypothetical patients undergo state transitions according to a state transition model, and calculates a profit distribution as shown in FIG. 7 by aggregating the profits of the 10,000 patients.

[0071] In any of the states of primary treatment 301, follow-up 302, secondary treatment 303, and follow-up 304, if it has been less than five years since the cell collection date, a payment is made to the pharmaceutical company's cold storage facility 30, but no sales are made. In any of the states of primary treatment 301, follow-up 302, secondary treatment 303, and follow-up 304, if it has been more than five years since the cell collection date, the cells are discarded due to deterioration, and the payment to the pharmaceutical company's cold storage facility 30 is 0 yen. If the state transitions from primary treatment 301, follow-up 302, secondary treatment 303, and follow-up 304 to death 307, the payment is 0 yen, and the simulation ends at this point. In the state of cell treatment 305, costs for cell processing and cell transportation between each facility are incurred. Furthermore, if five years have passed since the date of cell collection between the transition to primary treatment 301, follow-up observation 302, secondary treatment 303, and follow-up observation 304, the cells will be discarded due to deterioration, and the cells will need to be collected again, which will incur costs. The state of follow-up observation 306 means that the cell therapy did not fail, that is, the treatment was successful. Therefore, when the cell therapy transitions from cell therapy 305 to follow-up observation 306, the pharmaceutical company will receive reimbursement for the treatment costs from the patient for the first time, and can record this as sales.

[0072] By the above-described Monte Carlo simulation, the profit distribution is calculated for each combination of payment amount and storage period.

[0073] Next, the cell storage management system 202 determines whether or not to end the loop process of the payment amount (step S508).

[0074] If it is determined that the loop process of the payment amount is not to be ended, the cell storage management system 202 returns to step S506 and executes the same process.

[0075] If it is determined that the loop process of the payment amount is to be ended, the cell storage management system 202 determines whether or not to end the loop process of the storage period (step S509).

[0076] If it is determined that the loop process of the storage period is not to be ended, the cell storage management system 202 returns to step S504 and executes the same process.

[0077] When it is determined that the loop process of the storage period is to be ended, the cell storage management system 202 calculates the expected distribution of the out-of-pocket expenses using the out-of-pocket expense acceptance curve (step S510).

[0078] Specifically, the cell storage management system 202 calculates the burden amount from the payment amount selected in the simulation, and calculates the acceptance probability using the burden amount and the burden acceptance curve. Furthermore, the cell storage management system 202 calculates the product of the acceptance probability and the burden amount. By performing the same process for each payment amount, the expected distribution of the burden amount is calculated.

[0079] Next, the cell storage management system 202 determines whether or not to end the patient loop process (step S511).

[0080] If it is determined that the loop process for the patient is not to be ended, the cell storage management system 202 returns to step S503 and executes the same process.

[0081] When it is determined that the loop process for the patient is to be ended, the cell storage management system 202 calculates the optimal payment amount and the optimal storage period based on the profit distribution (step S512).

[0082] Specifically, the cell storage management system 202 compares the average value of each profit distribution and selects the profit distribution with the maximum average value. The cell storage management system 202 calculates the payment amount and storage period associated with the selected profit distribution as the optimal payment amount and optimal storage period. In this way, the optimal payment amount and optimal storage period are rational payment amount and storage period that maximize the profit of the pharmaceutical company.

[0083] Next, the cell storage management system 202 calculates the average value of the expected distribution of the burden amount as the average burden amount (step S513).

[0084] Next, the cell storage management system 202 determines the payment amount based on the storage fee, the optimum payment amount, the optimum storage period, and the average burden amount (step S514). After that, the cell storage management system 202 ends the cost calculation process.

[0085] Specifically, the cell storage management system 202 calculates the negotiated amount using formula (6). The breakdown of the storage fee is as shown in FIG.

[0086]

number

[0087] The pharmaceutical company determines the negotiated amount based on a comprehensive assessment of its business condition, the patient's condition, etc., and then determines the payment amount that maximizes the total of the negotiated amount and profits.

[0088] The present invention allows pharmaceutical companies to store collected cells at a cost that maximizes profits, and improves the quality of life (QoL) of patients by improving treatment outcomes.

[0089] Although the cell storage management system 202 executes various processes, other systems may execute them. Also, systems not shown may execute them.

[0090] The present invention can also be applied to services that store cells using methods other than freezing.

[0091] The present invention is not limited to the above-mentioned embodiment, but includes various modified examples. For example, the above-mentioned embodiment describes the configuration in detail to easily explain the present invention, and the present invention is not necessarily limited to the configuration including all the described configurations. Also, it is possible to add, delete, or replace a part of the configuration of each embodiment with another configuration.

[0092] In addition, each of the above configurations, functions, processing units, processing means, etc. may be realized in part or in whole by hardware, for example, by designing them as integrated circuits. The present invention can also be realized by software program code that realizes the functions of the embodiments. In this case, a storage medium on which the program code is recorded is provided to a computer, and a processor included in the computer reads the program code stored in the storage medium. In this case, the program code itself read from the storage medium realizes the functions of the above-mentioned embodiments, and the program code itself and the storage medium storing it constitute the present invention. Examples of storage media for supplying such program code include flexible disks, CD-ROMs, DVD-ROMs, hard disks, SSDs (Solid State Drives), optical disks, magneto-optical disks, CD-Rs, magnetic tapes, non-volatile memory cards, ROMs, etc.

[0093] Furthermore, the program code for realizing the functions described in this embodiment can be implemented in a wide range of program or script languages, such as assembler, C / C++, perl, Shell, PHP, Python, Java (registered trademark), etc.

[0094] Furthermore, the program code of the software that realizes the functions of the embodiments may be distributed over a network and stored in a storage means such as a computer's hard disk or memory, or in a storage medium such as a CD-RW or CD-R, and the processor of the computer may read out and execute the program code stored in the storage means or storage medium.

[0095] In the above-mentioned embodiment, the control lines and information lines are shown as those considered necessary for the explanation, and not all the control lines and information lines are shown in the product. All the components may be connected to each other. [Explanation of symbols]

[0096] 10 Medical institutions 20 Inspection companies 30 Cold Storage Facilities 40 Cell Processing Center 200 Patient Management System 201 Treatment Outcome Management System 202 Cell Storage Management System 203 Cell Processing Management System 210 Patient management DB 211 Treatment results management DB 212 Cell management DB 213 Processing management DB

Claims

1. 1. A computer system comprising: a computer having a processor, a storage device connected to the processor, and a network interface connected to the processor; A storage facility for storing cells collected from a patient, a processing facility for processing the stored cells, and a medical facility for performing cell therapy using the processed cells are accessible; The storage fee paid to the storage facility according to the storage period is borne by the patient and the operator of the processing facility, The business entity receives a success fee for the cell therapy from the patient; The processor calculates a probability of performing the cell therapy using treatment outcome data managed by the medical facility, and stores the calculated probability in the storage device. the processor generates a second model by incorporating an evaluation model for evaluating deterioration of the stored cells over time into a first model that calculates a success probability of the cell therapy, the first model being generated using characteristics of the cells collected from the patient who underwent the cell therapy and the treatment outcome data of the patient, and stores the second model in the storage device; The processor executes a simulation using the probability of performing the cell therapy and the second model to vary the storage period of the cells in the storage facility and the payment amount of the business operator to the storage facility, and estimates the profit of the business operator due to the success of the cell therapy, and stores the result of the simulation in the storage device. The computer system is characterized in that the processor calculates an optimal storage period and an optimal payment amount that maximize the profit of the business operator based on a result of the simulation.

2. 2. The computer system of claim 1, In the simulation, the processor calculates a profit distribution of the business operator for each combination of the storage period and the payment amount; The computer system according to claim 1, wherein the processor calculates the optimum holding period and the optimum payment amount based on a plurality of the profit distributions.

3. 3. The computer system of claim 2, The storage device stores, as the evaluation model, a cell deterioration evaluation function having the storage period as a variable; the first model is a function that uses the characteristics of the cell as a variable; The computer system according to claim 1, wherein the processor generates the second model by multiplying the first model by the evaluation model.

4. 4. The computer system of claim 3, The storage device stores a probability model for calculating a probability that the patient will accept the amount of the patient's contribution to the storage facility, based on the amount of the patient's contribution; The processor uses the probability model to calculate an expected distribution of the burden amount when the burden amount is varied, and stores the calculated expected distribution in the storage device; The processor calculates an average cost-sharing amount for the patient using the expected distribution of the cost-sharing amount and stores the calculated average cost-sharing amount in the storage device; The computer system according to claim 1, wherein the processor calculates the payment amount based on the storage fee, the optimal payment amount, and the average burden amount.

5. 3. The computer system of claim 2, The computer system is characterized in that the cell characteristics are at least one of gene mutation, gene expression, and a gene set involved in cell growth and cell death.

6. A method for calculating a payment for a cell therapy using cells collected from a patient, the method comprising the steps of: The computer system comprises: a computer having a processor, a storage device connected to the processor, and a network interface connected to the processor; A storage facility for storing cells collected from a patient, a processing facility for processing the stored cells, and a medical facility for performing cell therapy using the processed cells are accessible; The storage fee paid to the storage facility according to the storage period is borne by the patient and the operator of the processing facility, The business entity receives a success fee for the cell therapy from the patient; The method of calculating the payment amount is as follows: A first step in which the processor calculates a probability of performing the cell therapy using treatment outcome data managed by the medical facility and stores the calculated probability in the storage device; a second step of the processor generating a second model by incorporating an evaluation model for evaluating deterioration of the stored cells over time into a first model for calculating a success probability of the cell therapy, the first model being generated using characteristics of the cells collected from the patient who underwent the cell therapy and the treatment outcome data of the patient, and storing the second model in the storage device; A third step in which the processor executes a simulation using the probability of performing the cell therapy and the second model to vary the storage period of the cells in the storage facility and the payment amount of the business operator to the storage facility, and estimates the profit of the business operator due to the success of the cell therapy, and stores the result of the simulation in the storage device; A fourth step in which the processor calculates, based on the results of the simulation, an optimal storage period and an optimal payment amount that maximize the profits of the business operator.

7. A method for calculating a payment amount according to claim 6, comprising the steps of: The third step includes a step of calculating a profit distribution of the business operator for each combination of the storage period and the payment amount by the processor, The method for calculating a payment amount, wherein the fourth step includes a step in which the processor calculates the optimal storage period and the optimal payment amount based on a plurality of the profit distributions.

8. A method for calculating a payment amount according to claim 7, comprising the steps of: The storage device stores, as the evaluation model, a cell deterioration evaluation function having the storage period as a variable; the first model is a function that uses the characteristics of the cell as a variable; The method of calculating a payment amount, wherein the second step includes a step of the processor generating the second model by multiplying the first model by the valuation model.

9. A method for calculating a payment amount according to claim 8, comprising the steps of: The storage device stores a probability model for calculating a probability that the patient will accept the amount of the patient's contribution to the storage facility, based on the amount of the patient's contribution; The method of calculating the payment amount is as follows: a step of the processor calculating an expected distribution of the amount of burden when the amount of burden is varied using the probability model, and storing the expected distribution in the storage device; The processor calculates an average cost-sharing amount for the patient using the expected distribution of the cost-sharing amount, and stores the calculated average cost-sharing amount in the storage device; and a step in which the processor calculates the payment amount based on the storage fee, the optimal payment amount, and the average burden amount.

10. A method for calculating a payment amount according to claim 7, comprising the steps of: The method for calculating a payment amount, wherein the cell characteristic is at least one of gene mutation, gene expression, and a gene set related to cell growth and cell death.

Images